Santhera Pharmaceuticals

Focus: Santhera Pharmaceuticals is a Swiss-based specialty pharmaceutical company focused on orphan neuromuscular disease targets, operating in the rare disease and neurology segments.

Neurology Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Santhera Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Santhera Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

9 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RHODOS Follow-up Single-visit Study

Leber's Hereditary Optic Neuropathy

N/A

Clinical Trials (1)

NCT01421381RHODOS Follow-up Single-visit Study

N/A

Help build intelligence for Santhera Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused therapeutic expertise in high-unmet-need orphan neuromuscular diseases with less competitive talent markets
Swiss headquarters provides access to European regulatory pathways and rare disease development networks
Specialized niche focus allows deeper domain expertise in neurology and rare disease development

Watch Out For

Zero active job postings suggest minimal current hiring or potential organizational contraction
Missing financial data (revenue, R&D spend, cash position) signals potential stability concerns or private status uncertainty

Generated by Claude from Santhera Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neur

Leber's Hereditary Optic Neuropathy (LHON)

N/A

Clinical Trials (1)

NCT02796274Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)

N/A

Idebenone 150 MG Oral Tablet

Leber's Hereditary Optic Neuropathy

N/A

Clinical Trials (1)

NCT04381091Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study

N/A

Idebenone

Duchenne Muscular Dystrophy

N/A

Clinical Trials (1)

NCT03433807Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)

N/A

Vamorolone

Duchenne Muscular Dystrophy

N/A

Clinical Trials (1)

NCT03863119Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy

N/A

Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families

Duchenne Muscular Dystrophy

N/A

Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey

Leber Hereditary Optic Neuropathy (LHON)

N/A

Clinical Trials (1)

NCT01892943Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey

N/A

Idebenone

Leber's Hereditary Optic Neuropathy (LHON)

N/A

Clinical Trials (1)

NCT02771379Post Authorisation Safety Study With Raxone in LHON Patients

N/A

Raxone

Drug-Drug Interaction

Phase 1

Clinical Trials (1)

NCT02887443A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate

Phase 1

Vamorolone

Pharmacodynamic

Phase 1

Clinical Trials (1)

NCT06649409Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects

Phase 1

Omigapil

Congenital Muscular Dystrophy

Phase 1

Clinical Trials (1)

NCT01805024Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)

Phase 1

Vamorolone

Drug Interaction

Phase 1

Clinical Trials (1)

NCT06689527Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics

Phase 1

POL6014

Cystic Fibrosis

Phase 1/2

Clinical Trials (1)

NCT03748199Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF